Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Adenosine receptor antagonist (1) ·
Adenosine receptor antagonist; dopaminergic (1) ·
Adenosine receptor antagonist; phosphodiesterase inhibitor (1) ·
Alpha-adrenergic agonist; monoamine releaser (1) ·
Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) ·
AMPA modulator; catecholaminergic (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
Dopamine and serotonin reuptake inhibitor; actoprotector (1) ·
Dopamine reuptake inhibitor; tropane analogue (1) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Indirect sympathomimetic; norepinephrine releaser (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (10) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Monoamine reuptake inhibitor; sodium channel blocker (1) ·
N-methyl analogue of 2-AI (1) ·
Nicotinic acetylcholine receptor agonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine releaser (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Norepinephrine–dopamine reuptake inhibitor (2) ·
Potent dopamine and norepinephrine reuptake inhibitor (1) ·
Potent dopamine/norepinephrine reuptake inhibitor (1) ·
Selective norepinephrine reuptake inhibitor (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1) ·
'"`UNIQ--vote-00001014-QINU`"' Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. The dipropionate, valerate, and augmented dipropionate ester forms determine topical potency (high to super-high)'"`UNIQ--ref-00001015-QINU`"'. (1)
uses:
None (57) ·
'"`UNIQ--vote-00000E23-QINU`"', '"`UNIQ--vote-00000E24-QINU`"', '"`UNIQ--vote-00000E25-QINU`"', '"`UNIQ--vote-00000E26-QINU`"', '"`UNIQ--vote-00000E27-QINU`"', '"`UNIQ--vote-00000E28-QINU`"', '"`UNIQ--vote-00000E29-QINU`"', '"`UNIQ--vote-00000E2A-QINU`"' (1) ·
'"`UNIQ--vote-00001016-QINU`"', '"`UNIQ--vote-00001017-QINU`"', '"`UNIQ--vote-00001018-QINU`"', '"`UNIQ--vote-00001019-QINU`"' (1)
starting dose:
None (57) ·
Antenatal: Celestone Soluspan 12 mg IM q24h × 2 doses; topical: pea-sized amount BID; intra-articular varies by joint (1) ·
Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg) (1)
preparations:
None (57) ·
0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; oral solution; 4, 10, 20, 100 mg/mL IV; intravitreal implant (Ozurdex) (1) ·
0.6 mg/5 mL oral solution; Celestone Soluspan 6 mg/mL IM/IA (mix of sodium phosphate + acetate); 0.05% and 0.1% topical cream/ointment/lotion/foam (various salts); augmented betamethasone 0.05% (super-high potency) (1)
fda max:
routes:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 61 results in range #1 to #61.